ArticleCurrent oncology (Toronto, Ont.)2026
Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial.
Gai Yamashita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.